The assessment of disease activity in patients affected by Systemic Lupus Erythematosus (SLE) represents an important issue, as recommended by the European League Against Rheumatism (EULAR). Two main types of disease activity measure have been proposed: the global score systems, providing an overall measure of activity, and the individual organ/system assessment scales, assessing disease activity in different organs. All the activity indices included both clinical and laboratory items, related to the disease manifestations. However, there is no gold standard to measure disease activity in patients affected by SLE. In this review, we will analyze the lights and shadows of the disease activity indices, by means of a critical approach. In particular, we will focus on SLE Disease Activity Index (SLEDAI) and British Isles Lupus Assessment Group (BILAG), the most frequently used in randomized controlled trials and observational studies. The evaluation of data from the literature underlined some limitations of these indices, making their application in clinical practice difficult and suggesting the possible use of specific tools in the different subset of SLE patients, in order to capture all the disease features.

Assessment of disease activity in Systemic Lupus Erythematosus: Lights and shadows / Ceccarelli, Fulvia; Perricone, Carlo; Massaro, Laura; Cipriano, Enrica; Alessandri, Cristiano; Spinelli, FRANCESCA ROMANA; Valesini, Guido; Conti, Fabrizio. - In: AUTOIMMUNITY REVIEWS. - ISSN 1568-9972. - STAMPA. - 14:7(2015), pp. 601-608. [10.1016/j.autrev.2015.02.008]

Assessment of disease activity in Systemic Lupus Erythematosus: Lights and shadows

CECCARELLI, FULVIA;PERRICONE, CARLO;MASSARO, LAURA;CIPRIANO, ENRICA;ALESSANDRI, cristiano;SPINELLI, FRANCESCA ROMANA;VALESINI, Guido;CONTI, FABRIZIO
2015

Abstract

The assessment of disease activity in patients affected by Systemic Lupus Erythematosus (SLE) represents an important issue, as recommended by the European League Against Rheumatism (EULAR). Two main types of disease activity measure have been proposed: the global score systems, providing an overall measure of activity, and the individual organ/system assessment scales, assessing disease activity in different organs. All the activity indices included both clinical and laboratory items, related to the disease manifestations. However, there is no gold standard to measure disease activity in patients affected by SLE. In this review, we will analyze the lights and shadows of the disease activity indices, by means of a critical approach. In particular, we will focus on SLE Disease Activity Index (SLEDAI) and British Isles Lupus Assessment Group (BILAG), the most frequently used in randomized controlled trials and observational studies. The evaluation of data from the literature underlined some limitations of these indices, making their application in clinical practice difficult and suggesting the possible use of specific tools in the different subset of SLE patients, in order to capture all the disease features.
File allegati a questo prodotto
File Dimensione Formato  
Ceccarelli_ Assessment_2015.pdf

solo utenti autorizzati

Tipologia: Altro materiale allegato
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 521.48 kB
Formato Adobe PDF
521.48 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/882284
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 44
social impact